Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
Kidney Blood Press Res. 2009; 32(4):276-83.KB

Abstract

BACKGROUND

High cardiovascular risk in patients with chronic kidney disease (CKD) may be related to mineral disorder and microinflammation. Fibroblast growth factor 23 (FGF-23) is a phosphatonin and inhibitor of calcitriol synthesis, which is associated with poor prognosis in CKD patients starting dialysis. Matrix-metalloproteinases (MMP-2, MMP-9) contribute to myocardial remodeling and arterial calcification. FGF-23 and MMPs levels are altered in CKD, however, little is known about their association and relation to cardiovascular (CV) disease.

METHODS

Standard laboratory parameters, plasma levels of MMP-2, MMP-9, FGF-23, PAPP-A and CV disease history were assessed in 80 patients with CKD 1-5 and 44 healthy control subjects.

RESULTS

FGF-23 and MMP-2 (assessed by ELISA) were higher in CKD patients compared to controls. FGF-23 increased from CKD 3, whereas MMP-2 increased only in CKD 5. FGF-23 was positively associated with MMP-2, adjusted to age, eGFR, phosphatemia, calcitriol and parathormone. FGF-23 independently correlated with parathormone and inversely with calcitriol, whereas MMP-2 was related to phosphatemia. FGF-23 was higher in subjects with a history of CV disease compared to those free of such history (559.0 vs.184.0 RU/ml), adjusted to age and eGFR.

CONCLUSION

Our data suggest a possible relationship between FGF-23, MMP-2 and CV disease in CKD. Potential causality of this association remains to be elucidated.

Authors+Show Affiliations

Department of Nephrology, First Faculty of Medicine, Charles University, Hradec Králové, Czech Republic. mpeiskerova @ seznam.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19797911

Citation

Peiskerová, M, et al. "Fibroblast Growth Factor 23 and Matrix-metalloproteinases in Patients With Chronic Kidney Disease: Are They Associated With Cardiovascular Disease?" Kidney & Blood Pressure Research, vol. 32, no. 4, 2009, pp. 276-83.
Peiskerová M, Kalousová M, Kratochvílová M, et al. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res. 2009;32(4):276-83.
Peiskerová, M., Kalousová, M., Kratochvílová, M., Dusilová-Sulková, S., Uhrová, J., Bandúr, S., Malbohan, I. M., Zima, T., & Tesar, V. (2009). Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney & Blood Pressure Research, 32(4), 276-83. https://doi.org/10.1159/000243050
Peiskerová M, et al. Fibroblast Growth Factor 23 and Matrix-metalloproteinases in Patients With Chronic Kidney Disease: Are They Associated With Cardiovascular Disease. Kidney Blood Press Res. 2009;32(4):276-83. PubMed PMID: 19797911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? AU - Peiskerová,M, AU - Kalousová,M, AU - Kratochvílová,M, AU - Dusilová-Sulková,S, AU - Uhrová,J, AU - Bandúr,S, AU - Malbohan,I M, AU - Zima,T, AU - Tesar,V, Y1 - 2009/10/01/ PY - 2009/01/15/received PY - 2009/07/31/accepted PY - 2009/10/3/entrez PY - 2009/10/3/pubmed PY - 2009/12/31/medline SP - 276 EP - 83 JF - Kidney & blood pressure research JO - Kidney Blood Press Res VL - 32 IS - 4 N2 - BACKGROUND: High cardiovascular risk in patients with chronic kidney disease (CKD) may be related to mineral disorder and microinflammation. Fibroblast growth factor 23 (FGF-23) is a phosphatonin and inhibitor of calcitriol synthesis, which is associated with poor prognosis in CKD patients starting dialysis. Matrix-metalloproteinases (MMP-2, MMP-9) contribute to myocardial remodeling and arterial calcification. FGF-23 and MMPs levels are altered in CKD, however, little is known about their association and relation to cardiovascular (CV) disease. METHODS: Standard laboratory parameters, plasma levels of MMP-2, MMP-9, FGF-23, PAPP-A and CV disease history were assessed in 80 patients with CKD 1-5 and 44 healthy control subjects. RESULTS: FGF-23 and MMP-2 (assessed by ELISA) were higher in CKD patients compared to controls. FGF-23 increased from CKD 3, whereas MMP-2 increased only in CKD 5. FGF-23 was positively associated with MMP-2, adjusted to age, eGFR, phosphatemia, calcitriol and parathormone. FGF-23 independently correlated with parathormone and inversely with calcitriol, whereas MMP-2 was related to phosphatemia. FGF-23 was higher in subjects with a history of CV disease compared to those free of such history (559.0 vs.184.0 RU/ml), adjusted to age and eGFR. CONCLUSION: Our data suggest a possible relationship between FGF-23, MMP-2 and CV disease in CKD. Potential causality of this association remains to be elucidated. SN - 1423-0143 UR - https://www.unboundmedicine.com/medline/citation/19797911/Fibroblast_growth_factor_23_and_matrix_metalloproteinases_in_patients_with_chronic_kidney_disease:_are_they_associated_with_cardiovascular_disease L2 - https://www.karger.com?DOI=10.1159/000243050 DB - PRIME DP - Unbound Medicine ER -